TEVA in the 13F filings
Teva Pharmaceutical Inds LTD · CUSIP 881624209
- Quarter end
- 30 Jun 2025
- the date the book describes
- Filed
- 14 Aug 2025
- latest of these filings; the earliest 30 Jul 2025
- Managers listing it
- 11
- at least, of 95 tracked, among listed positions
- Comparable managers
- 95
- filed both Q1 2025 and Q2 2025; 10 listed it in both
- Shares listed
- 106,164,576
- combined, among listed positions
- Reported value
- $1.8bn
- combined, at the quarter end
Among the 95 comparable managers: 6 buyers (opened or added shares) and 5 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing TEVA in Q2 2025
11 of 11 holders
Largest increases and reductions, by shares
Increases
- Maverick Capital Ltdexisting position · 4,377,690 shares now+4,347,398
- Greenlight Capitalexisting position · 3,778,777 shares now+3,210,577
- Viking Global Investors LPexisting position · 11,681,333 shares now+1,555,855
- Glenview Capital Management LLCexisting position · 15,824,223 shares now+1,045,582
- ARK Investment Management LLCexisting position · 120,874 shares now+30,621
Reductions
- Fidelity (FMR LLC)existing position · 58,135,616 shares now-24,606,400
- Renaissance Technologies LLCexisting position · 3,156,982 shares now-2,144,263
- Holocene Advisors LPexisting position · 3,053,340 shares now-967,288
- Janus Henderson Group Ltdexisting position · 5,164,890 shares now-913,351
- Woodline Partners LPexisting position · 724,910 shares now-319,700
New positions and exits
New (0)
No new position among listed positions.
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2013 | 14 | $5.5bn | n.a. | n.a. |
| Q3 2013 | 16 | $5.9bn | n.a. | n.a. |
| Q4 2013 | 17 | $5.4bn | n.a. | n.a. |
| Q1 2014 | 24 | $7.7bn | n.a. | n.a. |
| Q2 2014 | 24 | $7.3bn | n.a. | n.a. |
| Q3 2014 | 25 | $7.4bn | n.a. | n.a. |
| Q4 2014 | 25 | $8.1bn | n.a. | n.a. |
| Q1 2015 | 25 | $8.7bn | n.a. | n.a. |
| Q2 2015 | 26 | $8.2bn | n.a. | n.a. |
| Q3 2015 | 23 | $8.4bn | n.a. | n.a. |
| Q4 2015 | 25 | $12.8bn | n.a. | n.a. |
| Q1 2016 | 27 | $10.3bn | n.a. | n.a. |
| Q2 2016 | 22 | $8.8bn | n.a. | n.a. |
| Q3 2016 | 25 | $7.9bn | n.a. | n.a. |
| Q4 2016 | 19 | $6.6bn | n.a. | n.a. |
| Q1 2017 | 22 | $5.9bn | n.a. | n.a. |
| Q2 2017 | 14 | $6.2bn | n.a. | n.a. |
| Q3 2017 | 15 | $3.0bn | n.a. | n.a. |
| Q4 2017 | 14 | $4.1bn | n.a. | n.a. |
| Q1 2018 | 13 | $4.8bn | n.a. | n.a. |
| Q2 2018 | 18 | $7.0bn | n.a. | n.a. |
| Q3 2018 | 18 | $6.3bn | n.a. | n.a. |
| Q4 2018 | 19 | $4.9bn | n.a. | n.a. |
| Q1 2019 | 14 | $4.7bn | n.a. | n.a. |
| Q2 2019 | 14 | $2.8bn | n.a. | n.a. |
| Q3 2019 | 11 | $2.0bn | n.a. | n.a. |
| Q4 2019 | 9 | $2.9bn | n.a. | n.a. |
| Q1 2020 | 14 | $2.0bn | n.a. | n.a. |
| Q2 2020 | 12 | $2.8bn | n.a. | n.a. |
| Q3 2020 | 7 | $2.1bn | n.a. | n.a. |
| Q4 2020 | 5 | $2.2bn | n.a. | n.a. |
| Q1 2021 | 8 | $2.6bn | n.a. | n.a. |
| Q2 2021 | 7 | $2.1bn | n.a. | n.a. |
| Q3 2021 | 6 | $1.7bn | n.a. | n.a. |
| Q4 2021 | 4 | $1.1bn | n.a. | n.a. |
| Q1 2022 | 9 | $1.4bn | n.a. | n.a. |
| Q2 2022 | 11 | $913m | n.a. | n.a. |
| Q3 2022 | 11 | $1.4bn | n.a. | n.a. |
| Q4 2022 | 11 | $1.7bn | n.a. | n.a. |
| Q1 2023 | 8 | $1.3bn | n.a. | n.a. |
| Q2 2023 | 10 | $184m | n.a. | n.a. |
| Q3 2023 | 13 | $384m | n.a. | n.a. |
| Q4 2023 | 10 | $373m | 8 | 3 |
| Q1 2024 | 16 | $666m | 8 | 6 |
| Q2 2024 | 22 | $1.8bn | 13 | 7 |
| Q3 2024 | 22 | $2.3bn | 9 | 12 |
| Q4 2024 | 18 | $3.0bn | 8 | 11 |
| Q1 2025 | 12 | $2.0bn | 7 | 6 |
| Q2 2025 | 11 | $1.8bn | 6 | 5 |
| Q3 2025 | 14 | $964m | 9 | 4 |
| Q4 2025 | 16 | $2.1bn | 18 | 22 |
| Q1 2026 | 14 | $2.0bn | 20 | 19 |
| Q2 2026 | 14 | $2.4bn | 18 | 16 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
TEVA and LLY →TEVA and JNJ →TEVA and VRTX →Choose a stock to compare with TEVA →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own TEVA, latest filings →Back to the 13F Explorer →